Adaptimmune is a leader in TCR T-cell therapy, focused on developing novel cancer immunotherapy products. We utilize the bodyâs own machinery â the T-cell â to target and destroy cancer cells by increasing the affinity of naturally occurring T-cell receptors (TCRs). We have developed a proprietary T-cell receptor platform that enables us to identify cancer targets, find and genetically engineer T-cell receptors, or TCRs, and produce TCR therapeutic candidates called SPEAR (Specific Peptide Enhanced Affinity Receptor) T-cells that recognize these targets on cancer cells. We engineer a patientâs own T-cells to express our SPEAR TCRs to target and potentially destroy tumors. Source
No articles found.
With a focus on the development of small molecule drugs for the treatment of cance...
With a focus on the development of small molecu...
Solid Biosciences is a life science company focused solely on finding meaningful t...
Solid Biosciences is a life science company foc...
Celcuity is a cellular analysis company that is discovering new cancer sub-types a...
Celcuity is a cellular analysis company that is...
Molecular Templates is focused on the discovery, development, and commercializatio...
Molecular Templates is focused on the discovery...
Fennec Pharmaceuticals, Inc., (NASDAQ: FENC; TSX: FRX) is a specialty pharmaceutic...
Fennec Pharmaceuticals, Inc., (NASDAQ: FENC; TS...
Akorn, Inc. is a niche pharmaceutical company that develops, manufactures and mark...
Akorn, Inc. is a niche pharmaceutical company t...
Curis is a biotechnology company focused on the development and commercialization ...
Curis is a biotechnology company focused on the...
Join the National Investor Network and get the latest information with your interests in mind.